Savior Lifetec (4167) - Total Liabilities

Latest as of December 2025: NT$403.30 Million TWD ≈ $12.71 Million USD

Based on the latest financial reports, Savior Lifetec (4167) has total liabilities worth NT$403.30 Million TWD (≈ $12.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Savior Lifetec's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Savior Lifetec - Total Liabilities Trend (2011–2025)

This chart illustrates how Savior Lifetec's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Savior Lifetec.

Savior Lifetec Competitors by Total Liabilities

The table below lists competitors of Savior Lifetec ranked by their total liabilities.

Company Country Total Liabilities
Josef Manner & Comp. AG
VI:MAN
Austria €88.81 Million
Bank Yudha Bhakti Tbk
JK:BBYB
Indonesia Rp14.07 Trillion
IM Vinaria Purcari SRL
RO:WINE
Romania RON491.95 Million
Formosa Oilseed Processing Co Ltd
TW:1225
Taiwan NT$3.81 Billion
HARIM Co. Ltd
KQ:136480
Korea ₩503.59 Billion
Autosports Group Ltd
AU:ASG
Australia AU$1.53 Billion
Studio City International Holdings Ltd
NYSE:MSC
USA $2.16 Billion
Oriental Interest Bhd
KLSE:5827
Malaysia RM869.55 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Savior Lifetec's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Savior Lifetec (4167) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 11.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Savior Lifetec's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Savior Lifetec (2011–2025)

The table below shows the annual total liabilities of Savior Lifetec from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 NT$403.30 Million
≈ $12.71 Million
-53.11%
2024-12-31 NT$860.02 Million
≈ $27.10 Million
+87.80%
2023-12-31 NT$457.96 Million
≈ $14.43 Million
-56.04%
2022-12-31 NT$1.04 Billion
≈ $32.82 Million
-15.01%
2021-12-31 NT$1.23 Billion
≈ $38.62 Million
-18.63%
2020-12-31 NT$1.51 Billion
≈ $47.46 Million
-17.20%
2019-12-31 NT$1.82 Billion
≈ $57.32 Million
+8.71%
2018-12-31 NT$1.67 Billion
≈ $52.73 Million
-6.21%
2017-12-31 NT$1.78 Billion
≈ $56.22 Million
+35.46%
2016-12-31 NT$1.32 Billion
≈ $41.51 Million
-20.32%
2015-12-31 NT$1.65 Billion
≈ $52.09 Million
-10.10%
2014-12-31 NT$1.84 Billion
≈ $57.94 Million
+34.23%
2013-12-31 NT$1.37 Billion
≈ $43.16 Million
+24.18%
2012-12-31 NT$1.10 Billion
≈ $34.76 Million
+8.16%
2011-12-31 NT$1.02 Billion
≈ $32.14 Million
--

About Savior Lifetec

TWO:4167 Taiwan Biotechnology
Market Cap
$190.72 Million
NT$6.05 Billion TWD
Market Cap Rank
#16821 Global
#819 in Taiwan
Share Price
NT$19.50
Change (1 day)
+2.09%
52-Week Range
NT$16.70 - NT$21.85
All Time High
NT$40.63
About

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more